FERNANDO CALVO BALTANAS

Dr. FERNANDO CALVO BALTANAS

CIC-IBMCC, Universidad de Salamanca-CSIC and CIBERONC, 37007 Salamanca, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2020 in Human Gene Therapy
Verified
Journal Article
Closed access
MCMichael J. Castle
Michael J. Castle
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
IKImre Kovacs
Imre Kovacs
ANAlan H. Nagahara
Alan H. Nagahara
DBDavid Barba
David Barba
MTMark H. Tuszynski
Mark H. Tuszynski
Nerve growth factor (NGF) gene therapy rescues and stimulates cholinergic neurons, which degenerate in Alzheimer's disease (AD). In a recent clinical trial for AD, intraparenchymal adeno-associated virus serotype 2 (AAV2)-NGF delivery was safe but did not improve cognition. Before concluding that NGF gene therapy is ineffective, it must be shown that AAV2-NGF successfully engaged the target cholinergic neurons of the basal forebrain. In this study, patients with clinically diagnosed early- to middle-stage AD received a total dose of 2 × 10 11 vector genomes of AAV2-NGF by stereotactic injection of the nucleus basalis of Meynert. After a mean survival of 4.0 years, AAV2-NGF targeting, spread, and expression were assessed by immunolabeling of NGF and the low-affinity NGF receptor p75 at 15 delivery sites in 3 autopsied patients. NGF gene expression persisted for at least 7 years at sites of AAV2-NGF injection. However, the mean distance of AAV2-NGF spread was only 0.96 ± 0.34 mm. NGF did not directly reach cholinergic neurons at any of the 15 injection sites due to limited spread and inaccurate stereotactic targeting. Because AAV2-NGF did not directly engage the target cholinergic neurons, we cannot conclude that growth factor gene therapy is ineffective for AD. Upcoming clinical trials for AD will utilize real-time magnetic resonance imaging guidance and convection-enhanced delivery to improve the targeting and spread of growth factor gene delivery.

1 November 2013 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
MPMartín Pérez-Andrés
Martín Pérez-Andrés
AGAlicia Ginel-Picardo
Alicia Ginel-Picardo
DDDavid Díaz
David Díaz
DJDavid Jimeno
David Jimeno
Eugenio SantosEugenio Santos
Eugenio Santos
Sos1 and Sos2 are ubiquitously expressed, universal Ras guanine nucleotide exchange factors (Ras-GEFs) acting in multiple signal transduction pathways activated by upstream cellular kinases. The embryonic lethality of Sos1 null mutants has hampered ascertaining the specific in vivo contributions of Sos1 and Sos2 to processes controlling adult organism survival or development of hematopoietic and nonhematopoietic organs, tissues, and cell lineages. Here, we generated a tamoxifen-inducible Sos1-null mouse strain allowing analysis of the combined disruption of Sos1 and Sos2 (Sos1/2) during adulthood. Sos1/2 double-knockout (DKO) animals died precipitously, whereas individual Sos1 and Sos2 knockout (KO) mice were perfectly viable. A reduced percentage of total bone marrow precursors occurred in single-KO animals, but a dramatic depletion of B-cell progenitors was specifically detected in Sos1/2 DKO mice. We also confirmed a dominant role of Sos1 over Sos2 in early thymocyte maturation, with almost complete thymus disappearance and dramatically higher reduction of absolute thymocyte counts in Sos1/2 DKO animals. Absolute counts of mature B and T cells in spleen and peripheral blood were unchanged in single-KO mutants, while significantly reduced in Sos1/2 DKO mice. Our data demonstrate functional redundancy between Sos1 and Sos2 for homeostasis and survival of the full organism and for development and maturation of T and B lymphocytes.

30 November 2010 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
ICIñigo Casafont
Iñigo Casafont
EWEduardo Weruaga
Eduardo Weruaga
JAJosé R Alonso
José R Alonso
MBMaría T Berciano
María T Berciano
MLMiguel Lafarga
Miguel Lafarga

1 August 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
ICIñigo Casafont
Iñigo Casafont
VLVanesa Lafarga
Vanesa Lafarga
EWEduardo Weruaga
Eduardo Weruaga
JAJosé R. Alonso
José R. Alonso
MLMiguel Lafarga
Miguel Lafarga
DNA repair protects neurons against spontaneous or disease-associated DNA damage. Dysfunctions of this mechanism underlie a growing list of neurodegenerative disorders. The Purkinje cell (PC) degeneration mutation causes the loss of nna1 expression and is associated with the postnatal degeneration of PCs. This PC degeneration dramatically affects nuclear architecture and provides an excellent model to elucidate the nuclear mechanisms involved in a whole array of neurodegenerative disorders. We used immunocytochemistry for histone variants and components of the DNA damage response, an in situ transcription assay, and in situ hybridization for telomeres to analyze changes in chromatin architecture and function. We demonstrate that the phosphorylation of H2AX, a DNA damage signal, and the trimethylation of the histone H4K20, a repressive mark, in extensive domains of genome are epigenetic hallmarks of chromatin in degenerating PCs. These histone modifications are associated with a large scale reorganization of chromatin, telomere clustering, and heterochromatin-induced gene silencing, all of them key factors in PC degeneration. Furthermore, ataxia telangiectasia mutated and 53BP1, two components of the DNA repair pathway, fail to be concentrated in the damaged chromatin compartments, even though the expression levels of their coding genes were slightly up-regulated. Although the mechanism by which Nna1 loss of function leads to PC neurodegeneration is undefined, the progressive accumulation of DNA damage in chromosome territories irreversibly compromises global gene transcription and seems to trigger PC degeneration and death.

18 August 2017 in Leukemia
Verified
Journal Article
Open access
PDF file
SGS Gerboth
S Gerboth
EFE Frittoli
E Frittoli
APA Palamidessi
A Palamidessi
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
MSM Salek
M Salek
GSG Scita
G Scita
Son of Sevenless 1 (SOS1) is a dual guanine nucleotide exchange factor (GEF) that activates the small GTPases RAC and RAS. Although the molecular mechanisms of RAS GEF catalysis have been unveiled, how SOS1 acquires RAC GEF activity and what is the physio-pathological relevance of this activity is much less understood. Here we show that SOS1 is tyrosine phosphorylated on Y1196 by ABL. Phosphorylation of Y1196 controls SOS1 inter-molecular interaction, is required to promote the exchange of nucleotides on RAC in vitro and for platelet-derived growth factor (PDGF) activation of RAC- and RAC-dependent actin remodeling and cell migration. SOS1 is also phosphorylated on Y1196 by BCR-ABL in chronic myelogenous leukemic cells. Importantly, in these cells, SOS1 is required for BCR-ABL-mediated activation of RAC, cell proliferation and transformation in vitro and in a xenograft mouse model. Finally, genetic removal of Sos1 in the bone marrow-derived cells (BMDCs) from Sos1fl/fl mice and infected with BCR-ABL causes a significant delay in the onset of leukemogenesis once BMDCs are injected into recipient, lethally irradiated mice. Thus, SOS1 is required for full transformation and critically contribute to the leukemogenic potential of BCR-ABL.

9 May 2016 in Oncogene
Verified
Journal Article
Closed access
PDF file
PLP Liceras-Boillos
P Liceras-Boillos
RGR García-Navas
R García-Navas
AGA Ginel-Picardo
A Ginel-Picardo
BAB Anta
B Anta
MPMartín Pérez-Andrés
Martín Pérez-Andrés
ESE Santos
E Santos